Global Health Policy
« A Woodstock Moment for Malaria | Main | Unusual Business At The WB-IMF Annual Meetings: Investing In AIDS Vaccines R & D »
October 19, 2007
Why Drug Resistance Makes Me Think About Global Warming
Posted by Ruth Levine at 11:42 AM
When I saw the headlines earlier this week about the toll of drug-resistant staph infection - Staph Fatalities May Exceed AIDS Deaths - I started thinking about global warming. This wasn't some anxiety-inducing exercise to tote up all the possible things that might wipe us off the planet, but rather a musing on how a big problem that's on the minds of scientists finally makes it onto the public policy agenda - and how important it is to make sure that the "rich world" orientation of both the scientific and the policy communities doesn't obscure the important "poor world" issues.
Here's how drug resistance writ large (not related only to staph, but also to TB, AIDS and malaria) is a little bit like global warming:
- Both are a result of profligate overuse of a precious resource (fossil fuels, the ability to kill harmful bugs) without mindfulness about long-term consequences.
- For both, we've created a situation in which the commercial interests are largely lined up against better resource management and mitigation measures. The power of markets and the private sector is not yet marshaled toward making the situation better. The energy sector makes money on oil not conservation; the pharmaceutical industry may see few gains from taking steps to ensure the long-term effectiveness of low-margin, first-line drugs.
- For both, the government has a crucial role to play in regulation and in providing incentives for better resource management - and in both cases governments have been slow to take on those tasks. Particularly in low-income countries, public officials may also see that actions to mitigate long-term damage have a near-term cost for economic development (if energy conservation is required) and improvements in health conditions (if it's necessary to slow drug access until stronger systems to ensure adherence are in place).
- Both can be ameliorated only with a combination of significant behavior changes (by consumers, health care workers, patients) and technological developments (energy-efficient cars, solar power, new diagnostics and drugs).
- For both, understanding the severity and causes of the problem, and the feasible solutions is only possible if we think about the planet as one world, with global goods - and bads - that call for collective action.
The threat of drug resistance has not yet broken through in a big way into public policy circles, despite the worrisome signs - the recent research on deaths from staph infection, the emergence of extensively drug-resistant TB, new findings about the high rates of ARV failure in Africa. If the global warming analogy is right, scientists will fret over this for many more years and will see their warnings dismissed in favor of more "convenient truths." And the contributing factors and potential solutions in developing countries will be largely ignored. By the time the policy makers start feeling the heat, alternative paths will be much more challenging to find and it will be still more difficult to bring on board decision makers in the developing world.
Maybe we can learn a bit from the global warming story, though, and figure out ways to focus attention on the issue of drug resistance earlier than would otherwise be the case, and to ensure that the issues from the perspective of developing countries is well integrated into the policy discussions. Certainly some excellent efforts toward raising awareness about antibiotic drug resistance in the US have been made by our friends at Resources for the Future and elsewhere - see, for example, Extending the Cure. Now it's time to work on understanding the breadth of this and other types of drug resistance in low-income countries - particularly where donors are having a strong hand in expanding access to drugs - and to identify measures to address the problem.
Note: CGD is hoping to contribute to that process through a new Drug Resistance Working Group, to be led by my colleague Rachel Nugent.
Trackback Ping
TrackBack URL for this entry:
/mt/mt-tb.cgi/996
Comments
Ruth - Your interesting post about the parallels between climate change and drug resistance leads me to wonder whether public information disclosure--which has proven effective in cutting conventional pollution, and which CGD is about to try for CO2 emissions (our soon-to-be released CARMA database) --might also be part of the solution for the drug resistance. Is there good, easily accessible data about where and when drug resistant cases arise? Could the incentives that the Working Group will examine be strengthened by making the data collection and disclosure on this more effective? Could color coding of localities to reward good performers and identify areas in need of improvement be helpful in strengthening positive incentives.
I suspect there is a wealth of experience in the use of public information for improved health outcomes. One that I know a little about is the California Healthcare Foundation's use of hospital ratings, CalHospitalCompare.org. The data itself is not new, but by collecting and sharing it in a way that ordinary people can access and understand they have strengthened the incentives for hospitals to improve the quality of care.
I wonder if by digging around in their database it would be possible to find information on drug resistant cases!
Posted by: Lawrence MacDonald at November 5, 2007 05:26 PM